A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Completed · Phase 2

Conditions studied: Age-Related Macular Degeneration

In brief

The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Key facts

Study ID

NCT02401945

Run by

Santen Inc.

People needed

16

Starts

2015-04-01

Expected to finish

2016-10-31

Last updated by the study team

2018-04-18

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provide signed written informed consent
• Diagnosis of active CNV secondary to wet AMD, with some subfoveal component in the study eye
• No evidence of subfoveal fibrosis or subfoveal RPE atrophy in the study eye
• At least one lesion in the study eye that meets minimal pathology criteria
• Best corrected visual acuity of 70 to 25 ETDRS letters in the study eye
• Best corrected visual acuity of 20/320 or better in the fellow eye
• Reasonably clear media and some fixation in the study eye

You may not qualify if…

• Ocular
• Aphakic or has an anterior chamber intraocular lens in the study eye
• Received prior treatment with anti-VEGF, intravitreal corticosteroids or photodynamic therapy in the study eye
• Uncontrolled glaucoma despite anti-glaucoma therapy in the study eye
• Evidence of any ocular disease other than AMD in the study eye that may confound the outcome of the study
• History of vitrectomy in the study eye
• Need for ocular surgery in the study eye during the course of the trial
• Presence or history of certain ocular or periocular pathology or conditions that could limit ability to perform required study assessments in either eye and/or confound study results
• Non-Ocular
• Allergy or hypersensitivity to study drug product, fluorescein dye or other study-related procedures and medications
• Current or history of certain systemic conditions, abnormalities or therapies that would render a subject a poor candidate for the study
• Participation in other investigational drug or device clinical trials within 30 days prior to randomization or planning to participate in other investigational drug or device clinical trials for the duration of the study
• Females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions and men who do not agree to practice an acceptable method of contraception throughout the course of the study
• Unable to comply with study procedures or follow-up visits

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Bakersfield, California, United States
• Study site — Walnut Creek, California, United States
• Study site — Golden, Colorado, United States
• Study site — Altamonte Springs, Florida, United States
• Study site — Fort Myers, Florida, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Portsmouth, New Hampshire, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Dallas, Texas, United States
• Study site — Houston, Texas, United States
• Study site — McAllen, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.